Navigation Links
NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
Date:5/12/2009

Hamburg, Germany and Copenhagen, Denmark, May 12th, 2009 / b3c newswire / – Richter-Helm BioLogics GmbH & Co. KG announces today a technological breakthrough in the field of purification of antibody fragments from an E. coli expression system. Richter-Helm BioLogics has finalized the downstream process for Phase III clinical trial material using 2nd Generation Expanded Bed Adsorption (EBA) technology developed by the Danish biotech company Upfront Chromatography A/S.

Having conducted a series of tests, Richter-Helm has discovered significant advantages of 2nd Generation EBA over the latest, alternative chromatographic methods. A 60% increase in yield was observed using direct capture.  The simplified process is less likely to cause processing problems.  The processing time to take product from homogenate to clarified, partially purified material was reduced to one working day, decreasing the possibility of product degradation.  The volume of buffers required to perform clarification and capture was reduced significantly, effecting cost of manufacture.

Upfront’s innovation lay in the usage of higher density adsorbents and the proprietary design of an operational system which provides increased flow rates and is free from clogging and channel formation.

Rhobust® has improved Richter-Helm’s offering to customers operating with microbial derived products, providing a superior downstream process for clinical manufacturing. Richter-Helm embraced this technology under tight timelines and cost pressures and has been rewarded with a superior downstream offering in the CMO market.

The Rhobust® universal processing platform from Upfront Chromatography enables customers to efficiently capture and purify monoclonal antibodies, therapeutic proteins and other biomolecules directly from blood plasma or bioreactors, without the need for prior filtration.  

Selection of proprietary mixed mode ligand chemistry enables efficient control of the capture and release of target molecules by simple changes of pH, which can be readily implemented in large-scale production facilities and maintain biological activity of the product. Mixed mode ligands are selected for their suitability for industrial processing, in particular their stability during high temperature cleaning with 1M NaOH, low toxicity, and very low leakage from adsorbent.


For further information please contact:

Richter-Helm:
Dr. Kai Pohlmeyer
Head of Business Development
Phone: +49-40-2375-2430  
Mail: k.pohlmeyer@richter-helm-biotec.eu

--> Meet us at Bio2009 Booth number 5222


Upfront :
Rob Noel
Global Manager
Business Development
Phone: +44 7970 930895,
Mail: robnoel@upfront-dk.com

Natalya Clark
Marketing/PR Manager
Phone:.+4539174337
Mail: nac@upfront-dk.com

--> Meet us at Bio2009 Booth number 5123 BioProcess Zone 


'/>"/>
b3c newswire

Related biology news :

1. Novel antibody prevents infection by hepatitis C virus
2. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
3. Antibody key to treating variant CJD, scientists find
4. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
5. ETH Zurich researchers develop antibody test
6. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
7. Yale chemist receives NIH Young Investigator Award for antibody targeting
8. Reversing cognitive deficits: Injectable antibody may attack source of problem
9. Fossil fragments reveal 500-million-year-old monster predator
10. The song doesnt remain the same in fragmented bird populations
11. EMBL scientists develop first fully automated pipeline for multiprotein complex production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... 20, 2016  As part of its longstanding mission to ... genetics company, recently released its latest children,s book, titled ... focuses on the topics of inheritance and variation of traits ... taught in elementary school classrooms in the US. ... illustrator Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Jan. 18, 2017 The global biotechnology ... 92.9 billion by 2025, according to a new ... has been adaptive of the function of outsourcing ... 2002. Among the services outsourced, clinical trial management ... Johnson & Johnson was the first pharmaceutical company ...
(Date:1/19/2017)... -- Acupath Laboratories, Inc., a leading provider of sub-specialized ... Committee that will guide the company,s vision and strategy ... , a 15-year veteran of the anatomic pathology industry, ... Chief Sales Officer .  Prior to joining Acupath ... leadership roles at several leading lab industry organizations including, ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
Breaking Biology Technology: